ライフサイエンスコーパス: obliterative bronchiolitis

1 erative airway disease (OAD), a correlate of obliterative bronchiolitis.

2 to the small human airway grafts, and caused obliterative bronchiolitis.

3 rlying another chronic inflammatory disease, obliterative bronchiolitis.

4 tion-associated chronic complications, e.g., obliterative bronchiolitis.

5 s isolated from the airways of patients with obliterative bronchiolitis.

6 ine heterotopic tracheal allograft model for obliterative bronchiolitis.

7 mplicated in late graft failure secondary to obliterative bronchiolitis.

8 s in the mouse heterotopic tracheal model of obliterative bronchiolitis.

9 tology to study the airway injury related to obliterative bronchiolitis.

10 ave value in the prevention and treatment of obliterative bronchiolitis.

11 gainst the mesenchymal cell proliferation of obliterative bronchiolitis.

12 afts develop chronic rejection manifested as obliterative bronchiolitis.

13 baseline) and/or the presence of histologic obliterative bronchiolitis.

14 e (OAD) leading to a lesion resembling human obliterative bronchiolitis.

15 etely effective therapy for the treatment of obliterative bronchiolitis.

16 Obliterative bronchiolitis after lung transplantation is

17 The etiology and pathogenesis of obliterative bronchiolitis after lung transplantation re

18 ulate T-cell responses in the development of obliterative bronchiolitis after lung transplantation.

19 geneic immune response in the development of obliterative bronchiolitis after lung transplantation.

20 e critical role of T cells in development of obliterative bronchiolitis among human lung allograft re

21 s treated with CMVIG had lower incidences of obliterative bronchiolitis and death from obliterative b

22 of obliterative bronchiolitis and death from obliterative bronchiolitis and longer survival compared

23 Nine patients with histologic active obliterative bronchiolitis and progressively worsening a

24 In this study, we induced obliterative bronchiolitis and studied the contribution

25 isorders include constrictive bronchiolitis (obliterative bronchiolitis, bronchiolitis obliterans), a

26 tic cells (DC) is thought to be important in obliterative bronchiolitis/bronchiolitis obliterans synd

27 cessive amount of NO promotes posttransplant obliterative bronchiolitis by destroying airway epitheli

28 tes to the development of lung rejection and obliterative bronchiolitis by mediating effector T lymph

29 (angiographic); and incidence and death from obliterative bronchiolitis defined by pathological crite

30 logical lesions similar to those typical for obliterative bronchiolitis developed in vivo after recon

31 iogenesis during development of experimental obliterative bronchiolitis [ie, obliterative airway dise

32 ith cyclosporine, in preventing and treating obliterative bronchiolitis in heart-lung and lung allogr

33 hymal cells, which is a lesion comparable to obliterative bronchiolitis in human lung transplant reci

34 n with histologic features characteristic of obliterative bronchiolitis in human lung transplant reci

35 ubtypes all contribute to the development of obliterative bronchiolitis in the heterotopic mouse trac

36 nifestations of chronic rejection, including obliterative bronchiolitis, interstitial fibrosis, and o

37 Obliterative bronchiolitis is a frequent, morbid, and us

38 Obliterative bronchiolitis is the major cause of long-te

39 Chronic inflammation, a hallmark of obliterative bronchiolitis, is known to induce lymphangi

40 ication of lung transplantation, may promote obliterative bronchiolitis leading to graft failure in l

41 y of HO-1 accelerates the development of the obliterative bronchiolitis-like lesion.

42 Efforts to reduce the development of obliterative bronchiolitis may require the antagonism of

43 ose of this study was to investigate whether obliterative bronchiolitis might occur after xenogenic p

44 characterized by the pathologic findings of obliterative bronchiolitis: neutrophil influx and extrac

45 Obliterative bronchiolitis (OB) after lung transplantati

46 id into the lung mediates the development of obliterative bronchiolitis (OB) in orthotopic WKY-to-F34

47 Obliterative bronchiolitis (OB) is a clinical syndrome m

48 Obliterative bronchiolitis (OB) is a devastating complic

49 Obliterative bronchiolitis (OB) is a dreaded and frequen

50 Obliterative bronchiolitis (OB) is the histopathological

51 Obliterative bronchiolitis (OB) is the most serious late

52 Obliterative bronchiolitis (OB) is the primary cause of

53 Obliterative bronchiolitis (OB) post-lung transplantatio

54 Chronic allograft rejection manifested as obliterative bronchiolitis (OB) remains the single great

55 Actuarial probability of remaining free from obliterative bronchiolitis (OB)* tended to be higher in

56 Obliterative bronchiolitis (OB), an important threat to

57 syndrome and its histopathologic correlate, obliterative bronchiolitis (OB), are a major source of m

58 n bronchoalveolar lavage (BAL) had developed obliterative bronchiolitis (OB), but only 8 of the 38 su

59 Lung transplant survival is limited by obliterative bronchiolitis (OB), but the mechanisms of O

60 mmation, lymphocytic bronchiolitis (LB), and obliterative bronchiolitis (OB), causes substantial morb

61 Obliterative bronchiolitis (OB), chronic allograft rejec

62 Chronic lung allograft rejection, known as obliterative bronchiolitis (OB), is the leading cause of

63 Obliterative bronchiolitis (OB), or chronic allograft re

64 changed); both parameters correlated with an obliterative bronchiolitis (OB)-free state.

65 ut survival is limited by the development of obliterative bronchiolitis (OB).

66 ion, epithelial damage, and eventual luminal obliterative bronchiolitis (OB).

67 afts develop chronic rejection manifested as obliterative bronchiolitis (OB).

68 ajor histological features of posttransplant obliterative bronchiolitis (OB).

69 ognized small-airway histological process of obliterative bronchiolitis (OB).

70 isk factor for the subsequent development of obliterative bronchiolitis (OB).

71 ection, manifested as small airway fibrosis (obliterative bronchiolitis [OB]), is the main obstacle t

72 o develop a murine chimera model that mimics obliterative bronchiolitis of lung allograft recipients

73 ET-1 expression did not vary with rejection, obliterative bronchiolitis, or infection.

74 Obliterative bronchiolitis remains a major long-term com

75 assified as stable (DL-S, n = 11), or having obliterative bronchiolitis syndrome (DL-OBS, n = 4).

76 because of chronic rejection in the form of obliterative bronchiolitis syndrome (OBS).

77 These data show that in this murine model of obliterative bronchiolitis, these chemokines are differe

78 tatins during postoperative Year 1 developed obliterative bronchiolitis, whereas the cumulative incid

79 Mechanistic study of obliterative bronchiolitis would be aided by development